Elucid
PrivateLast Round
Series C
Nov 9, 2023
Total Funding Raised
$115.75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Elucid is a medical technology company that develops AI-powered imaging software to quantify and characterize atherosclerotic plaque for personalized cardiovascular disease treatment.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical AI, Healthcare Analytics, Medical Devices
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Elucid Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Elucid Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 9, 2023 | ||||
| Series B | Jun 22, 2022 | ||||
| Series A | May 10, 2021 | ||||
| Grant | Sep 1, 2015 |
Key People
Founding team and executive leadership
Elucid Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bold Brain | Series B |
| IAG Capital Partners | Series B, Series A |
| MedTex Ventures | Series B, Series C, Series A |
| NIH RADx | Grant |
| Bioverge | Series B |
| Willamette Valley Capital | Series A |
| Checkmate Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2026
Commercial availability of the Lesion Inspection Tool for plaque analysis.
- Aug 5, 2025
Shamiram Feinglass, M.D. joins the board of directors.
Elucid Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Elucid's valuation, stock price, and market status.